Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RPG Life SciencesNSE:RPGLIFE -1.17%89 EV-to-EBITDA is 21.44 as of Aug. 29, 2026, which is 63% above its 10-year median of 13.16. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 89/100 and a GF Value™ of ₹2,486.73 (Fairly Valued). The stock has 2 warning signs investors should review. Among 733 Drug Manufacturers companies, RPG Life Sciences ranks worse than 70.26% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, RPG Life Sciences's enterprise value is ₹39,426 Mil.
RPG Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹1,839 Mil. Therefore, RPG Life Sciences's EV-to-EBITDA for today is 21.44.
The historical rank and industry rank for RPG Life Sciences's EV-to-EBITDA or its related term are showing as below:
NSE:RPGLIFE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.07 Med: 13.16 Max: 36.34
Current: 21.44
During the past 13 years, the highest EV-to-EBITDA of RPG Life Sciences was 36.34. The lowest was 5.07. And the median was 13.16.
NSE:RPGLIFE's EV-to-EBITDA is ranked worse than 70.26% of 733
companies
in the Drug Manufacturers industry
Industry Median: 13.06
vs NSE:RPGLIFE: 21.44
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
RPG Life Sciences (NSE:RPGLIFE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
RPG Life Sciences's PE Ratio (TTM) for today is calculated as:
RPG Life Sciences's share price for today is ₹2537.60.
RPG Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹72.340.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for RPG Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RPG Life Sciences EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where RPG Life Sciences's EV-to-EBITDA falls into.
RPG Life Sciences's current Enterprise Value is ₹39,426 Mil.
RPG Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,839 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RPG Life Sciences (NSE:RPGLIFE) has a EV-to-EBITDA of 21.44 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on RPG Life Sciences. This is 63% above median its historical median of 13.16. Over the past decade, RPG Life Sciences' EV-to-EBITDA has ranged from 5.07 to 36.34. According to the industry distribution chart, RPG Life Sciences ranks #515 out of 733 companies in the Drug Manufacturers industry, placing it in the top 70.3%.
Is RPG Life Sciences' EV-to-EBITDA too high?
RPG Life Sciences' current EV-to-EBITDA of 21.44 is 63% above median its 10-year median of 13.16. Over the past 10 years, this metric has ranged from a low of 5.07 to a high of 36.34. The Drug Manufacturers industry median EV-to-EBITDA is 13.06. RPG Life Sciences' value of 21.44 is 64.2% above this industry median. Based on the distribution chart, RPG Life Sciences ranks #515 out of 733 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, RPG Life Sciences has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, RPG Life Sciences ranks #515 out of 733 companies for EV-to-EBITDA. This places RPG Life Sciences in the lower half of its industry. The industry median EV-to-EBITDA is 13.06. RPG Life Sciences' value of 21.44 is 64.2% above this benchmark. Historically, RPG Life Sciences' own EV-to-EBITDA has ranged from 5.07 to 36.34 over the past decade. While the company's 10-year median is 13.16 vs. the industry median of 13.06, RPG Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.06, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RPG Life Sciences's current EV-to-EBITDA of 21.44 is 64.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on RPG Life Sciences. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RPG Life Sciences's current EV-to-EBITDA is 21.44, which is 63% above median its own 10-year median of 13.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,486.73, compared to a current price of ₹2,537.60 — trading 2% above its estimated fair value. The current EV-to-EBITDA is 21.44, which is 63% above median its 10-year median of 13.16 and 64.2% above the Drug Manufacturers industry median of 13.06. RPG Life Sciences' overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current EV-to-EBITDA is 21.44 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, RPG Life Sciences stock appears to be overvalued.
The current stock price of ₹2,537.60 is trading 2% above its estimated GF Value™ of ₹2,486.73.
GuruFocus considers RPG Life Sciences to be Fairly Valued.
Key valuation signals for NSE:RPGLIFE:
EV-to-EBITDA: 21.44 (63% above median its 10-year median of 13.16)
GF Value™: ₹2,486.73 vs. price of ₹2,537.60 (2% above fair value)
Industry Position: 64.2% above the Drug Manufacturers median (#515 of 733)
No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
89GF Score
Get the complete analysis for NSE:RPGLIFE
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RPGLIFE has been successfully added to your 
